The role of miRNAs in the pheochromocytomas

Tumor Biology

Volumn 37, Issue 4, 2016, Pages 4235-4239

  Li, Zheng ^a   Yu, Xin ^a   Shen, Jianxiong ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

microRNAs; miRNAs; Paragangliomas; Pheochromocytoma

Indexed keywords

ATM PROTEIN; MESSENGER RNA; MICRORNA; MICRORNA 101; MICRORNA 1225; MICRORNA 139; MICRORNA 15A; MICRORNA 16; MICRORNA 195; MICRORNA 210; MICRORNA 483; MICRORNA 541; MICRORNA 765; MICRORNA 885; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; AREA UNDER THE CURVE; ARTICLE; ATM GENE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; DISEASE FREE SURVIVAL; EPITHELIAL MESENCHYMAL TRANSITION; GENE; GENE EXPRESSION REGULATION; GENE REPRESSION; GENETIC ASSOCIATION; HUMAN; MUTATIONAL ANALYSIS; NONHUMAN; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SDHB GENE; SURVIVAL RATE; SURVIVAL TIME; TRANSLATION REGULATION; UPREGULATION; ZNF367 GENE; ADRENAL GLAND NEOPLASMS; GENETICS; PATHOLOGY; PROGNOSIS; SURVIVAL ANALYSIS;

ADRENAL GLAND NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; PHEOCHROMOCYTOMA; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84944698812     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-4199-z     Document Type: Article

References (74)

1. Eisenhofer G, Peitzsch M. Laboratory evaluation of pheochromocytoma and paraganglioma. Clin Chem. 2014;60:1486–99.
2. Madias JE. A comparison of pheochromocytoma and takotsubo syndrome. Korean Circ J. 2014;44:446.
3. Ditkofsky N, Workman C. Pheochromocytoma supporting blood pressure in the setting of cardiogenic shock. Clin Imaging. 2015;39:136–9.
4. Chen Y, Hodin RA, Pandolfi C, Ruan DT, McKenzie TJ. Hypoglycemia after resection of pheochromocytoma. Surgery. 2014;156:1404–8. discussion 1408–1409.
5. Kim HJ, Lee JI, Cho YY, Lee SY, Kim JH, Jung BC, et al. Diagnostic accuracy of plasma free metanephrines in a seated position compared with 24-hour urinary metanephrines in the investigation of pheochromocytoma. Endocr J. 2015;62:243–50.
6. Bayley JP, Oldenburg RA, Nuk J, Hoekstra AS, van der Meer CA, Korpershoek E, et al. Paraganglioma and pheochromocytoma upon maternal transmission of sdhd mutations. BMC Med Genet. 2014;15:111.
7. Tschuor C, Sadri H, Clavien PA. Pheochromocytoma crisis. Clinical Case Rep. 2014;2:14.
8. Oshmyansky AR, Mahammedi A, Dackiw A, Ball DW, Schulick RD, Zeiger MA, et al. Serendipity in the diagnosis of pheochromocytoma. J Comput Assist Tomogr. 2013;37:820–3.
9. Balakrishnan G, Ravikumar R, Rao S, Balakrishnan KR. Tetralogy of fallot with pheochromocytoma: an unusual therapeutic challenge. Asian Cardiovasc Thorac Ann. 2013;21:464–6.
10. Rizak J, Tan H, Zhu H, Wang JF: Chronic treatment with the mood stabilizing drug lithium up-regulates nuclear factor e2-related factor 2 in rat pheochromocytoma pc12 cells in vitro. Neuroscience 2014;256:223–229.
11. Fudim M, Ely EW, Laffer CL, Elijovich F. Diagnosis of pheochromocytoma on physical examination. Eur Heart J. 2014;35:1705.
12. Kaku Y, Saito S, Saito H, Yamazaki K. On-pump beating resection of cardiac pheochromocytoma. Asian Cardiovasc Thorac Ann. 2014;22:89–91.
13. Haddad S, Al-Raiy B, Madkhali A, Al-Qahtani S, Al-Sultan M, Arabi Y. Cardiorespiratory crisis at the end of pregnancy: a case of pheochromocytoma. Middle East J Anaesthesiol. 2013;22:195–202.
14. Li W, Yang B, Che JP, Yan Y, Liu M, Li QY, et al. Diagnosis and treatment of extra-adrenal pheochromocytoma of urinary bladder: case report and literature review. Int J Clin Exp Med. 2013;6:832–9.
15. Bausch B, Wellner U, Bausch D, Schiavi F, Barontini M, Sanso G, et al. Long-term prognosis of patients with pediatric pheochromocytoma. Endocr Relat Cancer. 2014;21:17–25.
16. Baskok FA, Senturk B, Ozeke O, Aras D. Recurrence of cardiomyopathy by recurrent pheochromocytoma. Int J Cardiol. 2013;169:e31–2.
17. Mohammed AA, El-Shentenawy AM, Sherisher MA, El-Khatib HM. Target therapy in metastatic pheochromocytoma: current perspectives and controversies. Oncol Rev. 2014;8:249.
18. Barski D. Management and follow up of extra-adrenal phaeochromocytoma. Central Eur J Urology. 2014;67:156–61.
19. Jochmanova I, Zelinka T, Widimsky Jr J, Pacak K. HIF signaling pathway in pheochromocytoma and other neuroendocrine tumors. Physiol Res. 2014;63 Suppl 2:S251–62.
20. Li J, Yang CH. Improvement of preoperative management in patients with adrenal pheochromocytoma. Int J Clinical Exp Med. 2014;7:5541–6.
21. Lambelin M, Meuris B, Bogaert J, Eggermont N, Sinnaeve PR. Pheochromocytoma as an incidentaloma in severe symptomatic calcified constrictive pericarditis. Acta Cardiol. 2014;69:566–7.
22. Thosani S, Ayala-Ramirez M, Palmer L, Hu MI, Rich T, Gagel RF, et al. The characterization of pheochromocytoma and its impact on overall survival in multiple endocrine neoplasia type 2. J Clin Endocrinol Metab. 2013;98:E1813–9.
23. Rijken JA, Niemeijer ND, Corssmit EP, Jonker MA, Leemans CR, Menko FH, Hensen EF: Low penetrance of paraganglioma and pheochromocytoma in an extended kindred with a germline sdhb exon 3 deletion. Clinical Genet 2015. doi:10.1111/cge.12591.
24. Yu X, Li Z. The role of microRNAs expression in laryngeal cancer. Oncotarget 2015;6(27):23297–305.
25. Li Z, Yu X, Shen J, Law PT, Chan MT, Wu WK. MicroRNA expression and its implications for diagnosis and therapy of gallbladder cancer. Oncotarget. 2015;6(16):13914–12.
26. Li Z, Yu X, Shen J, Chan MT, Wu WK. MicroRNA in intervertebral disc degeneration. Cell Prolif. 2015;48(3):278–83.
27. Yu X, Li Z, Liu J. Mirnas in primary cutaneous lymphomas. Cell proliferation 2015; 48:271–7.
28. Luo X, Dong Z, Chen Y, Yang L, Lai D. Enrichment of ovarian cancer stem-like cells is associated with epithelial to mesenchymal transition through an miRNA-activated AKT pathway. Cell Prolif. 2013;46:436–46.
29. Li M, Yu M, Liu C, Zhu H, He X, Peng S, et al. Mir-34c works downstream of p53 leading to dairy goat male germline stem-cell (mGSCs) apoptosis. Cell Prolif. 2013;46:223–31.
30. Li Z, Yu X, Shen J, Jiang Y. MicroRNA dysregulation in uveal melanoma: a new player enters the game. Oncotarget. 2015;6(7):4562–8.
31. Li Z, Yu X, Shen J, Wu WK, Chan MT. MicroRNA expression and its clinical implications in Ewing’s sarcoma. Cell Prolif. 2015;48:1–6.
32. Yu X, Li Z. MicroRNAs regulate vascular smooth muscle cell functions in atherosclerosis (review). Int J Mol Med. 2014;34:923–33.
33. Yu X, Li Z, Shen J, Wu WK, Liang J, Weng X, et al. MicroRNA-10b promotes nucleus pulposus cell proliferation through RhoC-Akt pathway by targeting HOXD10 in intervetebral disc degeneration. PLoS One. 2013;8, e83080.
34. Li J, You T, Jing J. Mir-125b inhibits cell biological progression of Ewing’s sarcoma by suppressing the PI3k/Akt signalling pathway. Cell Prolif. 2014;47:152–60.
35. Huang J, Zhang SY, Gao YM, Liu YF, Liu YB, Zhao ZG, et al. MicroRNAs as oncogenes or tumour suppressors in oesophageal cancer: potential biomarkers and therapeutic targets. Cell Prolif. 2014;47:277–86.
36. Li Z, Lei H, Luo M, Wang Y, Dong L, Ma Y, et al. DNA methylation downregulated mir-10b acts as a tumor suppressor in gastric cancer. Gastric Cancer. 2015;18:43–54.
37. Li Z, Yu X, Wang Y, Shen J, Wu WK, Liang J, Feng F. By downregulating tiam1 expression, microrna-329 suppresses gastric cancer invasion and growth. Oncotarget 2015;6:17559–69.
38. Ohdaira H, Sekiguchi M, Miyata K, Yoshida K. MicroRNA-494 suppresses cell proliferation and induces senescence in A549 lung cancer cells. Cell Prolif. 2012;45:32–8.
39. Fu LL, Yang Y, Xu HL, Cheng Y, Wen X, Ouyang L, et al. Identification of novel caspase/autophagy-related gene switch to cell fate decisions in breast cancers. Cell Prolif. 2013;46:67–75.
40. Hohjoh H, Fukushima T. Marked change in microRNA expression during neuronal differentiation of human teratocarcinoma NTera2D1 and mouse embryonal carcinoma P19 cells. Biochem Biophys Res Commun. 2007;362:360–7.
41. Meyer-Rochow GY, Jackson NE, Conaglen JV, Whittle DE, Kunnimalaiyaan M, Chen H, et al. MicroRNA profiling of benign and malignant pheochromocytomas identifies novel diagnostic and therapeutic targets. Endocr Relat Cancer. 2010;17:835–46.
42. Tombol Z, Eder K, Kovacs A, Szabo PM, Kulka J, Liko I, et al. MicroRNA expression profiling in benign (sporadic and hereditary) and recurring adrenal pheochromocytomas. Mod Pathol. 2010;23:1583–95.
43. Patterson E, Webb R, Weisbrod A, Bian B, He M, Zhang L, et al. The microRNA expression changes associated with malignancy and SDHB mutation in pheochromocytoma. Endocr Relat Cancer. 2012;19:157–66.
44. Hamada N, Fujita Y, Kojima T, Kitamoto A, Akao Y, Nozawa Y, et al. MicroRNA expression profiling of NGF-treated pc12 cells revealed a critical role for miR-221 in neuronal differentiation. Neurochem Int. 2012;60:743–50.
45. de Cubas AA, Leandro-Garcia LJ, Schiavi F, Mancikova V, Comino-Mendez I, Inglada-Perez L, et al. Integrative analysis of miRNA and mRNA expression profiles in pheochromocytoma and paraganglioma identifies genotype-specific markers and potentially regulated pathways. Endocr Relat Cancer. 2013;20:477–93.
46. Castro-Vega LJ, Letouze E, Burnichon N, Buffet A, Disderot PH, Khalifa E, et al. Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas. Nat Commun. 2015;6:6044.
47. Ding L, Zhao L, Chen W, Liu T, Li Z, Li X. Mir-210, a modulator of hypoxia-induced epithelial-mesenchymal transition in ovarian cancer cell. Int J Clinical Exp Med. 2015;8:2299–307.
48. McCormick RI, Blick C, Ragoussis J, Schoedel J, Mole DR, Young AC, et al. miR-210 is a target of hypoxia-inducible factors 1 and 2 in renal cancer, regulates ISCU and correlates with good prognosis. Br J Cancer. 2013;108:1133–42.
49. Osugi J, Kimura Y, Owada Y, Inoue T, Watanabe Y, Yamaura T, et al. Prognostic impact of hypoxia-inducible miRNA-210 in patients with lung adenocarcinoma. J Oncol. 2015;2015:316745.
50. Gee HE, Camps C, Buffa FM, Patiar S, Winter SC, Betts G, et al. Hsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. Cancer. 2010;116:2148–58.
51. Lai NS, Wu DG, Fang XG, Lin YC, Chen SS, Li ZB, et al. Serum microRNA-210 as a potential noninvasive biomarker for the diagnosis and prognosis of glioma. Br J Cancer. 2015;112(Suppl):1241–6.
52. Tsang VH, Dwight T, Benn DE, Meyer-Rochow GY, Gill AJ, Sywak M, et al. Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours. Endocr Relat Cancer. 2014;21:415–26.
53. Yongchun Z, Linwei T, Xicai W, Lianhua Y, Guangqiang Z, Ming Y, Guangjian L, Yujie L, Yunchao H: Microrna-195 inhibits non-small cell lung cancer cell proliferation, migration and invasion by targeting myb. Cancer letters 2014;347:65–74.
54. Zhou Y, Jiang H, Gu J, Tang Y, Shen N, Jin Y. MicroRNA-195 targets ADP-ribosylation factor-like protein 2 to induce apoptosis in human embryonic stem cell-derived neural progenitor cells. Cell Death Dis. 2013;4, e695.
55. Zhang QQ, Xu H, Huang MB, Ma LM, Huang QJ, Yao Q, et al. MicroRNA-195 plays a tumor-suppressor role in human glioblastoma cells by targeting signaling pathways involved in cellular proliferation and invasion. Neuro Oncol. 2012;14:278–87.
56. Yang X, Yu J, Yin J, Xiang Q, Tang H, Lei X. Mir-195 regulates cell apoptosis of human hepatocellular carcinoma cells by targeting LATS2. Pharmazie. 2012;67:645–51.
57. Li D, Zhao Y, Liu C, Chen X, Qi Y, Jiang Y, et al. Analysis of mir-195 and mir-497 expression, regulation and role in breast cancer. Clin Cancer Res. 2011;17:1722–30.
58. Deng H, Guo Y, Song H, Xiao B, Sun W, Liu Z, et al. MicroRNA-195 and microRNA-378 mediate tumor growth suppression by epigenetical regulation in gastric cancer. Gene. 2013;518:351–9.
59. Wang L, Qian L, Li X, Yan J. MicroRNA-195 inhibits colorectal cancer cell proliferation, colony-formation and invasion through targeting CARMA3. Mol Med Rep. 2014;10:473–8.
60. Liu B, Qu J, Xu F, Guo Y, Wang Y, Yu H, et al. Mir-195 suppresses non-small cell lung cancer by targeting CHEK1. Oncotarget. 2015;6:9445–56.
61. Guo H, Li W, Zheng T, Liu Z. Mir-195 targets HDGF to inhibit proliferation and invasion of NSCLC cells. Tumour Biol. 2014;35:8861–6.
62. You XY, Huang JH, Liu B, Liu SJ, Zhong Y, Liu SM. HMGA1 is a new target of mir-195 involving isoprenaline-induced cardiomyocyte hypertrophy. Biochem Biokhimiia. 2014;79:538–44.
63. Wang X, Wang Y, Lan H, Li J. MiR-195 inhibits the growth and metastasis of NSCLC cells by targeting IGF1R. Tumour Biol. 2014;35:8765–70.
64. Jain M, Zhang L, Boufraqech M, Liu-Chittenden Y, Bussey K, Demeure MJ, et al. ZNF367 inhibits cancer progression and is targeted by miR-195. PLoS One. 2014;9, e101423.
65. Liu JJ, Lin XJ, Yang XJ, Zhou L, He S, Zhuang SM, et al. A novel AP-1/miR-101 regulatory feedback loop and its implication in the migration and invasion of hepatoma cells. Nucleic Acids Res. 2014;42:12041–51.
66. Lin X, Guan H, Li H, Liu L, Liu J, Wei G, et al. MiR-101 inhibits cell proliferation by targeting Rac1 in papillary thyroid carcinoma. Biomed Re. 2014;2:122–6.
67. Konno Y, Dong P, Xiong Y, Suzuki F, Lu J, Cai M, et al. MicroRNA-101 targets EZH, 2, MCL-1 and FOS to suppress proliferation, invasion and stem cell-like phenotype of aggressive endometrial cancer cells. Oncotarget. 2014;5:6049–62.
68. Wang L, Li L, Guo R, Li X, Lu Y, Guan X, et al. Mir-101 promotes breast cancer cell apoptosis by targeting Janus kinase 2. Cell Physiol Biochem. 2014;34:413–22.
69. Zhang K, Zhang Y, Ren K, Zhao G, Yan K, Ma B. Microrna-101 inhibits the metastasis of osteosarcoma cells by downregulation of ezh2 expression. Oncol Rep 2014;32:2143–9.
70. Zhang J, Han C, Zhu H, Song K, Wu T. MiR-101 inhibits cholangiocarcinoma angiogenesis through targeting vascular endothelial growth factor (VEGF). Am J Pathol. 2013;182:1629–39.
71. Chen S, Wang H, Ng WL, Curran WJ, Wang Y. Radiosensitizing effects of ectopic miR-101 on non-small-cell lung cancer cells depend on the endogenous miR-101 level. Int J Radiat Oncol Biol Phys. 2011;81:1524–9.
72. Sun Q, Liu T, Zhang T, Du S, Xie GX, Lin X, et al. MiR-101 sensitizes human nasopharyngeal carcinoma cells to radiation by targeting stathmin 1. Mol Med Rep. 2015;11:3330–6.
73. Yin J, Wang M, Jin C, Qi Q. Mir-101 sensitizes A549 NSCLC cell line to CDDP by activating caspase 3-dependent apoptosis. Oncol Lett. 2014;7:461–5.
74. Zong L, Meng L, Shi R. Role of miR-101 in pheochromocytoma patients with SDHD mutation. Int J Clin Exp Pathol. 2015;8:1545–54.